The Best Treatment Plan for your Transplant

What is MMDx?

 

MMDx is a test that uses a biopsy sample to accurately assess the health of your transplanted organ. Your physician can use the MMDx test results to develop a personalized plan for your post-transplant care.

 

How Does MMDx Work? 

 

MMDx measures the level of tiny fragments of DNA called mRNA. Different patterns of mRNA will appear depending on the health of your transplanted organ. By measuring this pattern and comparing it against a database, MMDx can help your physician determine the likelihood of rejection.

 

Normal mRNA vs. Abnormal mRNA

We take your transplant tissue, extract the DNA, then pull it apart. It interacts with the fragments on the chip surface and will allow us to identify which proteins are present in your transplant. We can also tell how much protein is present, so your clinician can adopt the right magnitude of rejection treatment. 

mRNA is produced inside

transplanted tissue when DNA genes are expressed or active.

 

Depending on the risk or severity of organ rejection and injury, particular genes will be activated and produce unique patterns of mRNA.

 

MMDx accurately analyzes

thousands of different mRNA to provide you and your doctor precise information about the health of your transplanted organ to create a personalized treatment plan.

What does this mean for you? 

 

MMDx testing simply requires you to undergo a traditional tissue biopsy. A biopsy is a common medical test for transplant recipients usually performed by a surgeon and involves the extraction of sample cells (or tissues) for examination to determine the presence or extent of a disease, such as organ rejection. 

 

Following biopsy, the sample will be sent directly to our centralized testing laboratory and the results with be sent back within 28 hours with an in-depth detailed report. This data will guide your clinician in the correct and most effective course of treatment.  

MMDx is more convenient for you. A traditional biopsy assessment reduces the risk of inadequate or sub-optimal biopsy samples, which often results in having to take additional biopsy samples and increases the time delay before you receive the treatment you require.

© 2017-2019 by Thermo Fisher Scientific Inc.

  • Black LinkedIn Icon
  • Black Twitter Icon